TABLE 2.

Performance of AST-GN69 and AST-NX06 cards compared to BMD for 91 P. aeruginosa isolates

Antimicrobiala	BPb	No. of isolatesc				Performance (no. [%])d
		Total	R	I	S	EA	CA	VMEs	MEs	mEs
TZP	V2	91	21	0	70	90 (98.9)	88 (96.7)	0 (0)	3 (4.3)	0 (0)
	CLSI	91	21	11	59	90 (98.9)	86 (94.5)	0 (0)	0 (0)	5 (5.5)
Cefepime	V2/C	91	14	14	63	91 (100)	81 (89.0)	0 (0)	0 (0)	10 (11.0)
Ceftazidime	V2/C	91	16	9	66	91 (100)	83 (91.2)	0 (0)	0 (0)	8 (8.8)
Doripenem	V2	91	35	0	56	88 (96.7)	82 (90.1)	0 (0)	9 (16.1)	0 (0)
	CLSI	91	22	13	56	88 (96.7)	70 (76.9)	0 (0)	1 (1.8)	20 (22.0)
Imipenem	V2	91	31	6	54	91 (100)	84 (92.3)	0 (0)	0 (0)	7 (7.7)
	CLSI	91	37	4	50	91 (100)	88 (96.7)	0 (0)	0 (0)	3 (3.3)
Meropenem	V2	91	25	10	56	91 (100)	84 (92.3)	0 (0)	0 (0)	7 (7.7)
	CLSI	91	34	5	52	91 (100)	89 (97.8)	0 (0)	0 (0)	2 (2.2)
Amikacin	V2/C	91	2	2	87	91 (100)	91 (100)	0 (0)	0 (0)	0 (0)
Gentamicin	V2/C	91	10	0	81	90 (98.9)	79 (86.8)	0 (0)	0 (0)	12 (13.2)
Tobramycin	V2/C	91	8	0	83	91 (100)	90 (98.9)	0 (0)	0 (0)	1 (1.1)
Ciprofloxacin	V2/C	91	23	5	63	91 (100)	88 (96.7)	0 (0)	0 (0)	3 (3.3)
Levofloxacin	V2/C	91	27	10	54	91 (100)	88 (96.7)	0 (0)	0 (0)	3 (3.3)

^aTZP, piperacillin-tazobactam.

^bBP, breakpoint used to interpret MIC results; V2/C, Vitek 2 and CLSI M100S 26th edition breakpoints are the same; V2, Vitek 2 reported breakpoints; CLSI, M100S 26th edition breakpoints.

^cR, resistant; I, intermediate; S, susceptible.

^dEA, essential agreement (MIC ±1 doubling dilution); CA, categorical agreement; VMEs, very major errors; MEs, major errors; mEs, minor errors.